PUK16 COST-EFFECTIVENESS OF VALGANCICLOVIR 200 DAYS PROPHYLAXIS VERSUS 100 DAYS PROPHYLAXIS IN KIDNEY TRANSPLANT PATIENTS AT HIGH-RISK FOR DEVELOPING CYTOMEGALOVIRUS DISEASE
May 1, 2011, 00:00 AM
10.1016/j.jval.2011.02.431
https://www.valueinhealthjournal.com/article/S1098-3015(11)00570-5/fulltext
Section Title :
Disease-Specific Studies
Section Order :
990
First Page :
A77
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00570-5&doi=10.1016/j.jval.2011.02.431